Arterial Network learned that on June 11, US Eastern Time, the Wall Street Journal reported that medical device manufacturer Stryker and rival Boston Scientific had reached an acquisition merger agreement. If the deal is completed, it will create a medical device giant with a valuation of more than $110 billion. It is reported that the current valuation of Boston Scientific is about $44 billion, while Stryker's valuation is close to $67 billion. However, the Wall Street Journal said it is unclear whether Boston Science will eventually accept the offer of Stryker. Currently, representatives of Stryker and Boston Scientific declined to comment on the report. At 3:11 pm on New York time, Boston Scientific's share price rose 8% to $34.50, and Stryker shares fell 4% to $171.81. In the trading on the New York Stock Exchange on Monday, the trading of the two stocks was temporarily suspended. In fact, the two companies had cooperated a few years ago. Stryker acquired Boston Scientific's neurovascular business for $1.5 billion in 2010. Strong alliance, spawning 110 billion medical equipment giants The merger of Stryker and Boston Science will combine Stryker's expertise in orthopedics, neuroscience and spine surgery with Boston Scientific's business in cardiovascular and cardiac rhythm management to develop implantable devices, monitor the heart and provide Electricity to treat heart abnormalities. "If the news is accurate, it will create a medical device company with a valuation of more than $110 billion, second only to Medtronic and Johnson & Johnson," said Lawrence Biegelsen, a securities analyst at Wells Fargo Securities, in a research note. If a deal is reached, Stryker will receive Boston Scientific's line of cardiac devices, such as stents for supporting open obstructed arteries, defibrillators that correct dangerous heart rhythms, and Watchman devices that prevent blood clots from spreading around the heart. All of these devices reduce the risk of stroke. It is also said that Stryker will occupy a strong position in the prevention of stroke heart products. In recent years, large-scale merger transactions in the medical device field have been slowly developing. “It is important for all medical technology companies to provide a more comprehensive product portfolio to maintain and become the most valuable supplier to hospital customers. This portfolio can be sold to all “different hospitals†Morningstar Analyst Debbie Wang said. Earlier last year, Abbott completed a $25 billion acquisition of St. Jude, acquired its chronic pain management business, and enhanced its cardiovascular device products, such as devices for treating atrial fibrillation. In the largest transactions in the medical device sector, Medtronic completed a $43 billion acquisition of Covidien in early 2015. In 2014, Zimmer acquired Biomet for $13.3 billion. This is the merger of two major orthopaedic, surgical and dental products suppliers and the successful formation of Zimmer Biomet Holdings. Grain grinder,Flat Die,Flat Die Mould,Die Casting Mould,Flat Wood Moulding Shandong Longze Mechanical Equipment Co.,Ltd , https://www.pelletmachinefactory.com
Orthopedic giant Stryker plans to acquire Boston Scientific, a $110 billion medical device giant born!